Brown Advisory Inc. grew its holdings in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 5.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 594,021 shares of the biotechnology company’s stock after buying an additional 31,211 shares during the period. Brown Advisory Inc. owned 1.03% of Coherus Biosciences worth $7,930,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Coherus Biosciences by 88.8% in the 1st quarter. Vanguard Group Inc. now owns 2,209,244 shares of the biotechnology company’s stock valued at $46,726,000 after purchasing an additional 1,039,402 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Coherus Biosciences by 54.5% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock valued at $19,964,000 after purchasing an additional 490,899 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Coherus Biosciences by 70.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,001,104 shares of the biotechnology company’s stock valued at $14,366,000 after purchasing an additional 414,229 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Coherus Biosciences in the 2nd quarter valued at about $4,850,000. Finally, State Street Corp lifted its holdings in shares of Coherus Biosciences by 26.8% in the 2nd quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock valued at $20,329,000 after purchasing an additional 298,986 shares during the last quarter. 81.07% of the stock is owned by institutional investors.

CHRS has been the subject of several research reports. Zacks Investment Research raised Coherus Biosciences from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Tuesday, August 15th. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. J P Morgan Chase & Co reissued an “overweight” rating and issued a $25.00 target price (down from $32.00) on shares of Coherus Biosciences in a report on Tuesday, August 8th. Credit Suisse Group reissued an “outperform” rating and issued a $17.00 target price (down from $24.00) on shares of Coherus Biosciences in a report on Wednesday, September 27th. Finally, Maxim Group reissued a “buy” rating and issued a $20.00 target price (down from $40.00) on shares of Coherus Biosciences in a report on Friday, September 8th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Coherus Biosciences has a consensus rating of “Hold” and an average target price of $30.00.

Coherus Biosciences Inc (NASDAQ:CHRS) opened at $8.90 on Tuesday. Coherus Biosciences Inc has a 52-week low of $8.05 and a 52-week high of $29.59. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts predict that Coherus Biosciences Inc will post -4.39 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Coherus Biosciences Inc (CHRS) Holdings Increased by Brown Advisory Inc.” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2017/12/05/coherus-biosciences-inc-chrs-holdings-increased-by-brown-advisory-inc.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Institutional Ownership by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.